deltatrials
Completed PHASE1 NCT00960362

An Investigation of AGS-009 in Patients With Systemic Lupus Erythematosus (SLE)

A Randomised, Double-blind, Placebo-controlled, and Single Dose-escalation Trial of AGS-009 Administered in Subjects With Systemic Lupus Erythematosus

Sponsor: Argos Therapeutics

Conditions Inflammation Systemic Lupus Erythematosus (SLE)
Interventions AGS-009 placebo
Updated 6 times since 2017 Last updated: Jan 26, 2012 Started: Jul 31, 2009 Primary completion: Dec 31, 2011 Completion: Dec 31, 2011

Listed as NCT00960362, this PHASE1 trial focuses on Inflammation and Systemic Lupus Erythematosus (SLE) and remains completed. Sponsored by Argos Therapeutics, it has been updated 6 times since 2009, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Change History

6 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE1

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE1

  5. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE1

▶ Show 1 earlier version

  1. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE1

    First recorded

Jul 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Argos Therapeutics
Data source: Argos Therapeutics

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Birmingham, United States
  • • Dallas, United States
  • • Duncansville, United States
  • • Durham, United States
  • • Kansas City, United States
  • • Lake Success, United States